Research Into the Metastatic Mechanisms of Circulating Tumour Cells and The Application Value of Src/FN1 Pathway Inhibitors
DOI:
https://doi.org/10.54097/zkbwgh39Keywords:
CTC; Src/FN1 pathway; tumour metastasis.Abstract
Malignant tumours are extremely dangerous to human health, with at least a 90 percent death rate in cancer-related cases being a result of metastasis. Circulating tumour cells (CTCs) play a central role in the progression and spread of disease. Multiplexed stages in the metastasis process of circulating tumour cell (CTC) are: epithelial/mesenchymal transition (EMT), cluster formation in CTCs, as well as apoptosis resistance without homing, and vascular-extravasation, which are all closely related to the Src/FN1 pathway. The literature review methodology adopted in this review involved a systematic retrieval and analysis of topical literature by relying sufficiently on databases during the last ten years. Findings show that the Src/FN1 pathway controls CTC metastasis in a variety of ways, such as supporting EMT, sustaining the stability of CTC clusters, protecting CTCs against apoptosis, and supporting moving over blood vessels. Src/FN1 inhibitor has good therapeutic prospects, as it addresses the CTC metastasis process directly and complements the therapeutic effects of chemotherapy, targeted therapies, and immunotherapy. The review is a comprehensive explanation of the regulatory processes of this pathway in CTC metastasis, as it offers a theoretical background for further in-depth studies and clinical application of pertinent inhibitors.
Downloads
References
[1] Gerstberger S, Jiang Q, Ganesh K. Metastasis. Cell, 2023, 186(8): 1564-1579.
[2] Massagué J, Ganesh K. Metastasis-Initiating Cells and Ecosystems. Cancer Discov, 2021, 11(4): 971-994.
[3] Lambert AW, Pattabiraman DR, Weinberg RA. Emerging Biological Principles of Metastasis. Cell, 2017, 168(4): 670-691.
[4] Danfang Lin, Lesang Shen, Meng Luo, et al. Circulating tumor cells: biology and clinical significance. Sig Transduct Target Ther 6, 2021, 404.
[5] Xin Y, Li K, Yang M, Tan Y. Fluid Shear Stress Induces EMT of Circulating Tumor Cells via JNK Signaling in Favor of Their Survival during Hematogenous Dissemination. International Journal of Molecular Sciences, 2020, 21(21): 8115.
[6] Han, H. J., Song, J. Y., Kim, S. H., et al. Fibronectin regulates anti-cell detachment apoptosis through the formation of cellular aggregates. Cancer Communications, 2021, 508: 59-72.
[7] Huaman J, Ogunwobi OO. Circulating Tumor Cell Migration Requires Fibronectin Acting through Integrin B1 or SLUG. Cells, 2020, 9(7): 1594.
[8] Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol, 1994, 124(4): 619-26.
[9] Y. N. Kim, K. H. Koo, J. Y. Sung, et al. “Anoikis Resistance: An Essential Prerequisite for Tumor Metastasis”. International Journal of Cell Biology, Vol. 2012, 2012, Article
[10] Jean C, Gravelle P, Fournie JJ, Laurent G. Influence of stress on extracellular matrix and integrin biology. Oncogene, 2011, 30(24): 2697-706.
[11] Zhou W, Liu K, Zeng L, et al. Targeting VEGF-A/VEGFR2 Y949 Signaling-Mediated Vascular Permeability Alleviates Hypoxic Pulmonary Hypertension. Circulation, 2022, 146(24): 1855-1881.
[12] Fengyun Dong, Pinghui Zhou, Feifei Kong, et al. PCDH17 induces colorectal cancer metastasis by destroying the vascular endothelial barrier. Cell Death Dis 16, 2025, 36.
[13] Li X, Pan J, Liu T, Yin W, et al. Novel TCF21high pericyte subpopulation promotes colorectal cancer metastasis by remodelling perivascular matrix. Gut, 2023, 72(4): 710-721.
[14] Zujun Que et al. Src/FN1 pathway activation drives tumor cell cluster formation and metastasis in lung cancer: A promising therapeutic target. Sci, 2025, eadv7377.
[15] El Touny LH, Vieira A, Mendoza A, et al. Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells. J Clin Invest, 2014, 124(1): 156-68.
[16] Diaz-Jimenez A, Ramos M, Helm B, et al. Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome. Drug Resist Updat, 2024, 74: 101081.
[17] Yuan M, Xu LF, Zhang J, et al. SRC and MEK Co-inhibition Synergistically Enhances the Anti-tumor Effect in Both Non-small-cell Lung Cancer (NSCLC) and Erlotinib-Resistant NSCLC. Front Oncol, 2019, 9: 586.
[18] Poh AR, Love CG, Chisanga D, et al. Therapeutic inhibition of the SRC-kinase HCK facilitates T cell tumor infiltration and improves response to immunotherapy. Sci Adv, 2022, 8(25): eabl7882.
[19] Su Y, Zhu K, Wang J, et al. Advancing Src kinase inhibition: From structural design to therapeutic innovation - A comprehensive review. Eur J Med Chem, 2025, 287: 117369.
[20] Haura EB, Tanvetyanon T, Chiappori A, et al. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol, 2010, 28(8): 1387-94.
[21] Gold KA, Lee JJ, Harun N, et al. A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. Oncologist, 2014, 19(10): 1040-1.
[22] Algazi AP, Weber JS, Andrews SC, et al. Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. Br J Cancer, 2012, 106(1): 85-91.
[23] Li Z J, Zhao J D. Advances in Clinical Research on the CDK4/6 Inhibitors for HR+/HER2− Advanced Breast Cancer. Advances in Clinical Medicine, 2024, 14(3): 458-466.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
